Our data from this study is suggestive for a case for the prognostic classification of pancreatic cancer patients based on mutational status of KRAS and CDKN2A. However, the results need independent confirmation in additional studies with definite statistical confidence. The gene discussed is CDKN2A; the disease is familial pancreatic carcinoma.